A new treatment for drug-resistant epilepsy with the potential to suppress seizures ‘on demand’ with a pill, similar to how you might take painkillers when you feel a headache coming on, has been developed by UCL researchers funded by the Wellcome Trust.
The treatment, described in Nature Communications, combines genetic and chemical approaches to suppress seizures without disrupting normal brain function. The technique was demonstrated in rodents but in future we could see people controlling seizures on-demand with a simple pill.
Epilepsy affects around 50 million people worldwide including 600,000 in the UK and around a quarter of cases are resistant to conventional treatments. Many of these cases could be addressed by the new treatment method, which relies on genetic modification of brain cells to make them sensitive to a normally inactive compound.
The Latest on: Epilepsy treatment
via Google News
The Latest on: Epilepsy treatment
- Virginia Beach middle-schooler, Yorktown teen team up to make schools safer for students with epilepsyon January 12, 2020 at 5:46 am
The bill would allow parents and guardians to submit a seizure management and treatment plan that would outline the health services students ... who knows how to handle seizures and we’ll be safe,” ...
- Neurocrine, in Second Epilepsy Deal, Pairs With Swiss Biotech Idorsiaon January 11, 2020 at 12:22 am
Neurocrine is doubling down on epilepsy, striking its second agreement in as many months with a new deal that grants it the option to license an investigational treatment for a rare form of the ...
- BRIEF-Idorsia And Neurocrine Biosciences Amend Option Agreement On Treatment For Pediatric Epilepsyon January 9, 2020 at 10:43 pm
Our Standards:The Thomson Reuters Trust Principles.
- BRIEF-Neurocrine Biosciences And Idorsia Amend Option Agreement To License Novel Treatment For Rare Pediatric Epilepsyon January 9, 2020 at 10:31 pm
CLINICAL STAGE SELECTIVE T-TYPE CALCIUM CHANNEL BLOCKER FOR EPILEPSY TREATMENT * NEUROCRINE- UPON IND APPLICATION ACCEPTANCE BY U.S. FDA, EXPECTED MID-2020, CO WILL HAVE 30 DAYS TO EXERCISE OPTION ...
- Idorsia Pharmaceuticals Ltd: Neurocrine Biosciences and Idorsia amend option agreement to license novel treatment for rare pediatric epilepsyon January 9, 2020 at 9:05 pm
Neurocrine Biosciences owns option to exclusively license ACT-709478, a clinical stage selective T-type calcium channel blocker for the treatment of epilepsy Idorsia to receive $45 million upfront ...
- Neurocrine Biosciences and Idorsia Amend Option Agreement to License Novel Treatment for Rare Pediatric Epilepsyon January 9, 2020 at 9:00 pm
/PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) and Idorsia Ltd. (SIX: IDIA) announced an amendment to the agreement that was originally signed ...
- Long-term epilepsy-associated tumors: transcriptional signatures reflect clinical courseon January 9, 2020 at 3:17 am
Consequently, the oncological aspect should be also considered during the treatment decision-making process 21. Here, we present a comprehensive clinical, pathological and molecular analysis aiming at ...
- Odgers Berndtson awarded Epilepsy Foundation CEO Searchon January 7, 2020 at 4:42 pm
Odgers Berndtson, a top-six global executive search firm, is pleased to announce that they have been awarded the national search for the President and CEO for the Epilepsy Foundation. The search will ...
- Advances in Health: Next-Gen Treatment for Epilepsyon January 7, 2020 at 5:00 am
More than 2 million Americans will have a seizure at some point, but only one or two out of 100 actually have epilepsy. To get the most effective treatment, you must be diagnosed correctly. The ...
- Epilepsy study shows link between brain activity and memoryon January 6, 2020 at 7:36 am
Using electrodes implanted in the brains of 11 adult epilepsy patients as part of their treatment, the team recorded activity of individual cells in the hippocampus during a recognition memory task.
via Bing News